|
|
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).
Astrid Lièvre
,
Anthony Turpin
,
Isabelle Ray-Coquard
,
Karine Le Malicot
,
Juliette Thariat
et al.
Journal articles
hal-02998283v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: Analysis of aggregated data from a systematic literature review
Cindy Neuzillet
,
David Malka
,
Astrid Lièvre
,
Inderpreet Singh Khurana
,
Dewi Vernerey
et al.
Journal articles
hal-03781283v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer
Emeric Boisteau
,
Eric François
,
Thomas Aparicio
,
Karine Le Malicot
,
Rabia Boulahssass
et al.
Journal articles
hal-03632563v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Towards a RAS mutation status in a single day for patients with advanced colorectal cancers. Authors' Reply
Astrid Lièvre
,
Jean-Louis Merlin
,
Jean-Christophe Sabourin
,
Pascal Artru
,
Pierre Laurent-Puig
et al.
Journal articles
hal-01902490v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Should we screen for colorectal cancer in people aged 75 and over? A systematic review - collaborative work of the French geriatric oncology society (SOFOG) and the French federation of digestive oncology (FFCD)
Lydia Guittet
,
Valérie Quipourt
,
Thomas Aparicio
,
Elisabeth Carola
,
Jean-François Seitz
et al.
Journal articles
hal-03972097v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study
Côme Lepage
,
J-M. Phelip
,
Astrid Lièvre
,
Karine Le Malicot
,
L Dahan
et al.
Journal articles
hal-03810530v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014
Astrid Lièvre
,
Jean-Louis Merlin
,
Jean-Christophe Sabourin
,
Pascal Artru
,
Sabine Tong
et al.
Journal articles
hal-01778377v2
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
G.S. Roth
,
C. Neuzillet
,
M. Sarabi
,
J. Edeline
,
D Malka
et al.
Journal articles
hal-03931293v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer
Emeric Boisteau
,
Alexandra Lespagnol
,
Marie de Tayrac
,
Sébastien Corre
,
Anthony Perrot
et al.
Journal articles
hal-03595901v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Anterior gradient proteins in gastrointestinal cancers: from cell biology to pathophysiology
Emeric Boisteau
,
Céline Posseme
,
Federico Di Modugno
,
Julien Edeline
,
Cédric Coulouarn
et al.
Journal articles
hal-03798230v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Cancers colorectaux avec mutation V600E de BRAF : où en sommes-nous ?
Astrid Lièvre
,
Christelle de La Fouchardière
,
Emmanuelle Samalin
,
Stéphane Benoist
,
Jean-Marc Phelip
et al.
Journal articles
hal-03273660v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|